Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy Ihle NT; Powis GMol Cancer Ther 2009[Jan]; 8 (1): 1-9The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of the most exciting drug targets in oncology. However, only a short time ago, the paradigm existed that drugs targeted to the four PI3K class I isoforms would be too toxic for use in cancer therapy due to effects on physiologic signaling. Since that time, studies have delineated the roles of these four isoforms in nonpathologic signaling as well as their roles in cancer. An extensive effort has gone into developing agents that inhibit one or more PI3K isoforms, as well as closely related proteins implicated in cancer. These agents have proved to be tolerable and therapeutically beneficial in animal studies, and a number are in clinical testing. The agents, their properties, and their molecular targets are discussed in this review.|*Phosphoinositide-3 Kinase Inhibitors[MESH]|Animals[MESH]|Drug Discovery[MESH]|Humans[MESH]|Isoenzymes/antagonists & inhibitors/classification/metabolism[MESH]|Neoplasms/*drug therapy/*enzymology[MESH]|Phosphatidylinositol 3-Kinases/classification/*metabolism[MESH]|Protein Kinase Inhibitors/chemistry/*therapeutic use[MESH]|Signal Transduction[MESH] |